CN111655287B - Ildr2拮抗剂及其组合 - Google Patents

Ildr2拮抗剂及其组合 Download PDF

Info

Publication number
CN111655287B
CN111655287B CN201880077055.9A CN201880077055A CN111655287B CN 111655287 B CN111655287 B CN 111655287B CN 201880077055 A CN201880077055 A CN 201880077055A CN 111655287 B CN111655287 B CN 111655287B
Authority
CN
China
Prior art keywords
seq
antibody
ildr
fragment
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880077055.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111655287A (zh
Inventor
L.勒泽
U.格里灿
J.霍伊特
S.梁
A.鲍
J.洪特
O.莱维
I.瓦克宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Campugan Ltd
Bayer AG
Bayer Pharma AG
Original Assignee
Campugan Ltd
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Campugan Ltd, Bayer AG, Bayer Pharma AG filed Critical Campugan Ltd
Publication of CN111655287A publication Critical patent/CN111655287A/zh
Application granted granted Critical
Publication of CN111655287B publication Critical patent/CN111655287B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880077055.9A 2017-11-30 2018-11-28 Ildr2拮抗剂及其组合 Active CN111655287B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30
US62/592913 2017-11-30
PCT/EP2018/082779 WO2019105972A1 (en) 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof

Publications (2)

Publication Number Publication Date
CN111655287A CN111655287A (zh) 2020-09-11
CN111655287B true CN111655287B (zh) 2024-12-27

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880077055.9A Active CN111655287B (zh) 2017-11-30 2018-11-28 Ildr2拮抗剂及其组合

Country Status (16)

Country Link
US (1) US11655297B2 (enExample)
EP (1) EP3717007B1 (enExample)
JP (1) JP7350740B2 (enExample)
KR (1) KR20200096223A (enExample)
CN (1) CN111655287B (enExample)
AR (1) AR113850A1 (enExample)
AU (1) AU2018376231A1 (enExample)
BR (1) BR112020010767A2 (enExample)
CA (1) CA3083675A1 (enExample)
IL (1) IL274751B2 (enExample)
MX (1) MX2020005483A (enExample)
PE (1) PE20200956A1 (enExample)
RU (1) RU2020121533A (enExample)
SG (1) SG11202003323TA (enExample)
TW (1) TW201934119A (enExample)
WO (1) WO2019105972A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136510A1 (en) * 2019-04-11 2020-10-15 Bayer Aktiengesellschaft Combinations of anti-ildr2 antibodies and pd-1 antagonists
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2719728T3 (es) * 2007-09-04 2019-07-12 Compugen Ltd Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
AU2011272941B2 (en) * 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
CA2836855C (en) * 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US20170233473A1 (en) * 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
EP2756093A4 (en) * 2012-02-01 2015-07-01 Compugen Ltd C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
KR102186027B1 (ko) 2014-04-10 2020-12-03 다이이치 산쿄 유럽 게엠베하 항her3 항체-약물 콘주게이트
CA2998350A1 (en) 2015-09-16 2017-03-23 John Lippincott Anti-cd115 antibodies

Also Published As

Publication number Publication date
JP2021504404A (ja) 2021-02-15
KR20200096223A (ko) 2020-08-11
PE20200956A1 (es) 2020-09-24
RU2020121533A (ru) 2021-12-30
IL274751B2 (en) 2024-11-01
BR112020010767A2 (pt) 2020-11-24
AR113850A1 (es) 2020-06-17
CN111655287A (zh) 2020-09-11
EP3717007C0 (en) 2025-09-17
JP7350740B2 (ja) 2023-09-26
WO2019105972A1 (en) 2019-06-06
SG11202003323TA (en) 2020-05-28
IL274751B1 (en) 2024-07-01
TW201934119A (zh) 2019-09-01
AU2018376231A1 (en) 2020-05-07
IL274751A (en) 2020-07-30
MX2020005483A (es) 2020-08-27
EP3717007A1 (en) 2020-10-07
US20200369769A1 (en) 2020-11-26
EP3717007B1 (en) 2025-09-17
US11655297B2 (en) 2023-05-23
CA3083675A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
CN111655287B (zh) Ildr2拮抗剂及其组合
KR102616819B1 (ko) 폐암을 치료하기 위한 조성물 및 방법
KR102351556B1 (ko) 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
KR20240055852A (ko) D3-결합 분자 및 이의 용도
CN116940595A (zh) 抗tigit抗体及其用途
HK40028721A (en) Ildr2 antagonists and combinations thereof
HK40028721B (zh) Ildr2拮抗剂及其组合
TW202523352A (zh) 抗ｐｖｒｉｇ或ｔｉｇｉｔ的抗體、由其構建的雙特異性抗體、其製備方法和用途
HK40057228A (en) Combinations of anti-ildr2 antibodies and pd-1 antagonists
CN113645999A (zh) 抗ildr2抗体和pd-1拮抗剂的组合
EA042429B1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA045260B1 (ru) Композиции и способы для лечения рака легкого
NZ616809B2 (en) Anti-b7-h3 antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028721

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant